MyFinsight
Home
Blog
About
Contact
Download
Download image
Accounts receivable, net
$305,628K
Inventory
$125,586K
Cash and cash
equivalents
$79,148K
Short-term investment
securities
$62,822K
Other current assets
$57,580K
Total current assets
$630,764K
Deferred tax assets
$348,000K
Long-term investment
securities
$59,136K
Long-term inventory
$15,689K
Right of use assets
$6,278K
Other noncurrent
assets
$2,044K
Restricted cash
$1,342K
Total assets
$1,063,253K
Total liabilities and
stockholders equity
$1,063,253K
Total stockholders
equity
$648,020K
Total liabilities
$415,233K
Accumulated deficit
-$1,082,015K
Treasury stock, at cost,
3,543,643 and 367,903...
$100,234K
Additional paid-in capital
$1,830,110K
Loan payable
non-current
$245,645K
Total current
liabilities
$153,760K
Deferred revenue,
non-current portion
$8,807K
Lease liability
non-current
$7,021K
Common stock, 0.001 par
value per share...
$159K
Accounts payable and
accrued expenses
$107,508K
Accrued compensation
$21,850K
Deferred revenue -
current portion
$21,234K
Other current
liabilities
$2,124K
Lease liability
current portion
$1,044K
Back
Back
Balance Sheet
source: myfinsight.com
TG Therapeutics BRIUMVI Approval Call Slide Deck 12
TG THERAPEUTICS, INC. (TGTX)
TG Therapeutics BRIUMVI Approval Call Slide Deck 12
TG THERAPEUTICS, INC. (TGTX)